Related Experiment Videos

Heparin cofactor II in adults and infants with thrombosis and DIC

A Chuansumrit1, M J Manco-Johnson, W E Hathaway

  • 1Department of Pediatrics, University of Colorado School of Medicine, Denver 80262.

Insights

Heparin cofactor II (HC II) levels are lower in preterm and term infants due to immature liver function. Significantly reduced HC II activity was observed in infants with disseminated intravascular coagulation.

Area of Science:

  • Biochemistry
  • Pediatric Hematology
  • Coagulation Science

Background:

  • Heparin cofactor II (HC II) is a key inhibitor of thrombin.
  • Understanding HC II levels in neonates is crucial for assessing coagulation status.

Purpose of the Study:

  • To measure Heparin cofactor II (HC II) activity in preterm infants, full-term infants, and adults.
  • To investigate factors influencing HC II levels in different pediatric populations.

Main Methods:

  • Chromogenic activity assay was used to quantify HC II levels.
  • Study included normal preterm infants, normal full-term infants, and normal adults.
  • HC II activity was also assessed in specific patient groups, including those with thrombosis history, protein C/S deficiency, and disseminated intravascular coagulation.

Main Results:

  • Preterm infants (29%) and full-term infants (49%) showed lower HC II activity compared to adults (101%).
  • Children reached adult HC II levels by 5-7 months of age.
  • Significantly lower HC II activity was found in infants with disseminated intravascular coagulation.

Conclusions:

  • Lower HC II levels in neonates are likely due to immature liver function.
  • HC II activity is not significantly reduced in individuals with thrombosis history or protein C/S deficiency.
  • Disseminated intravascular coagulation is associated with markedly decreased HC II activity in infants.

Related Concept Videos